GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Island Pharmaceuticals Ltd (ASX:ILA) » Definitions » Notes Receivable

Island Pharmaceuticals (ASX:ILA) Notes Receivable : A$0.00 Mil (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Island Pharmaceuticals Notes Receivable?

Island Pharmaceuticals's Notes Receivable for the quarter that ended in Dec. 2024 was A$0.00 Mil.


Island Pharmaceuticals Notes Receivable Historical Data

The historical data trend for Island Pharmaceuticals's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Island Pharmaceuticals Notes Receivable Chart

Island Pharmaceuticals Annual Data
Trend Jun21 Jun22 Jun23 Jun24
Notes Receivable
- - - -

Island Pharmaceuticals Semi-Annual Data
Jun20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Notes Receivable Get a 7-Day Free Trial Premium Member Only - - - - -

Island Pharmaceuticals Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Island Pharmaceuticals Notes Receivable Related Terms

Thank you for viewing the detailed overview of Island Pharmaceuticals's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Island Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
c/- Bio101 Financial Advisory Pty Ltd, 697 Burke Road, Suite 201, Camberwell, Melbourne, VIC, AUS, 3124
Island Pharmaceuticals Ltd is a drug research and repurposing company focused on developing preventative or therapeutic drugs for viral infections. Its drug candidate ISLA-101 is a drug with a well-established safety profile, being repurposed for the prevention and treatment of dengue fever and another mosquito (or vector) borne diseases. The company carries out its research and development activities principally in the geographic regions of Australia and the United States of America.

Island Pharmaceuticals Headlines

No Headlines